Literature DB >> 9182982

Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin.

M G Kris, J E Radford, B A Pizzo, R Inabinet, A Hesketh, P J Hesketh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9182982     DOI： 10.1093/jnci/89.11.817

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  11 in total

Review 1.  Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.

Authors:  Steven M Grunberg; David Warr; Richard J Gralla; Bernardo L Rapoport; Paul J Hesketh; Karin Jordan; Birgitte T Espersen
Journal:  Support Care Cancer       Date:  2010-10-24       Impact factor: 3.603

2.  Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: What about the guidelines?

Authors:  Florence Van Ryckeghem
Journal:  J Transl Int Med       Date:  2016-04-14

3.  Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man.

Authors:  K Reid; J L Palmer; R J Wright; S A Clemes; C Troakes; H S Somal; F House; J R Stott
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

Review 4.  Potential of substance P antagonists as antiemetics.

Authors:  P Diemunsch; L Grélot
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

5.  Chemotherapy-induced nausea and vomiting in routine practice: a European perspective.

Authors:  Agnes Glaus; Cornelia Knipping; Rudolf Morant; Christel Böhme; Burkhard Lebert; Frank Beldermann; Bernhard Glawogger; Paz Fernandez Ortega; André Hüsler; Robert Deuson
Journal:  Support Care Cancer       Date:  2004-10       Impact factor: 3.603

Review 6.  Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments.

Authors:  Rudolph M Navari
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 7.  A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research.

Authors:  Gareth J Sanger; Paul L R Andrews
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.810

8.  Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015  Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis.

Authors:  Kenjiro Aogi; Hideki Takeuchi; Toshiaki Saeki; Keisuke Aiba; Kazuo Tamura; Keiko Iino; Chiyo K Imamura; Kenji Okita; Yoshikazu Kagami; Ryuhei Tanaka; Kazuhiko Nakagawa; Hirofumi Fujii; Narikazu Boku; Makoto Wada; Tatsuo Akechi; Hirotoshi Iihara; Shoichiro Ohtani; Ayako Okuyama; Keiko Ozawa; Yong-Il Kim; Hidenori Sasaki; Yasuo Shima; Masayuki Takeda; Eijiro Nagasaki; Toshihiko Nishidate; Takahiro Higashi; Kouichi Hirata
Journal:  Int J Clin Oncol       Date:  2020-11-08       Impact factor: 3.402

9.  Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics.

Authors:  R de Wit
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting.

Authors:  Chae Seong Lim; Young-Kwon Ko; Yoon-Hee Kim; Sang-Il Park; Jae-Kook Kim; Myoung-Joong Kim; Hyun-Joong Kim
Journal:  Korean J Anesthesiol       Date:  2013-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.